Dosimetry of internal emitters

Journal of Nuclear Medicine

Volumn 46, Issue 1 SUPPL., 2005, Pages

  Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absorbed dose; Radiobiologic modeling; Radionuclide therapy; Treatment planning

Indexed keywords

ANTINEOPLASTIC AGENT; RADIOISOTOPE;

ACCURACY; BONE MARROW; CANCER CHEMOTHERAPY; DOSE RESPONSE; DOSIMETRY; DRUG HALF LIFE; ENERGY ABSORPTION; EXTERNAL BEAM RADIOTHERAPY; GEOMETRY; HUMAN; KIDNEY PARENCHYMA; LEUKEMIA; POSITRON; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE THERAPY; REVIEW; TREATMENT PLANNING; ALGORITHM; ANIMAL; BIOLOGICAL MODEL; BODY BURDEN; CLINICAL PRACTICE; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER PROGRAM; ENERGY TRANSFER; METHODOLOGY; NEOPLASM; PATHOPHYSIOLOGY; RADIATION DOSE; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS;

ALGORITHMS; ANIMALS; BODY BURDEN; ENERGY TRANSFER; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; RADIOISOTOPES; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; SOFTWARE;

EID: 14844362344     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Hellman S. Principles of cancer management: radiation therapy. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:265-288.
2. Hall EJ. Radiobiology for the Radiologist. Philadelphia, PA: JB Lippincott Co.; 1994.
3. Browne E, Firestone RB. Table of Radioactive Isotopes. New York, NY: John Wiley & Sons; 1986.
4. Weber DA, Eckerman KF, Dillman LT, Ryman JC. MIRD: Radionuclide Data and Decay Schemes. New York, NY: Society of Nuclear Medicine; 1989.
5. Snyder WS, Fisher HL, Ford MR, Warner GG. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J Nucl Med. 1969;10(suppl):7S-52S.
6. Snyder WS, Ford MR, Warner GG. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. MIRD Pamplet No. 5, rev. New York, NY: Society of Nuclear Medicine; 1978.
7. Snyder WS, Ford MR, Warner GG, Watson SB. "S" Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11. New York, NY: Society of Nuclear Medicine; 1975.
8. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy at Various Ages for Internal Photon Sources. ORNL/TM-8381. Oak Ridge, TN: Oak Ridge National Laboratory; 1987.
9. Zanzonico PB. Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med. 2000;41:297-308.
10. Watson EE, Stabin MG, Davis JL, Eckerman KF. A model of the peritoneal cavity for use in internal dosimetry. J Nucl Med. 1989;30:2002-2011.
11. Stabin MG. A model of the prostate gland for use in internal dosimetry. J Nucl Med. 1994;35:516-520.
12. Bouchet LG, Bolch WE, Weber DA, Atkins HL, Poston JW Sr. MIRD pamphlet no. 15: radionuclide S values in a revised dosimetric model of the adult head and brain. J Nucl Med. 1999;40:62S-101S.
13. Mardirossian G, Tagesson M, Blanco P, et al. A new rectal model for dosimetry applications. J Nucl Med. 1999;40:1524-1531.
14. Bouchet LG, Bolch WE, Howell RW, Rao DV. S values for radionuclides localized within the skeleton. J Nucl Med. 2000;41:189-212.
15. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for 6 age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113-1147.
16. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994;35:303-316.
17. Goddu SM, Howell RL, Bouchet LG, Bolch WE, Rao DV. MIRD Cellular S Values. Reston, VA: Society of Nuclear Medicine; 1997.
18. Bolch WE, Bouchet LG, Robertson JS, et al. MIRD pamphlet no. 17: the dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. J Nucl Med. 1999;40:11S-36S.
19. Williams LE, Liu A, Raubitschek AA, Wong JY. A method for patient-specific absorbed dose estimation for internal beta emitters. Clin Cancer Res. 1999;5:3015s-3019s.
20. McKay E. A software tool for specifying voxel models for dosimetry estimation. Cancer Biother Radiopharm. 2003;18:379-392.
21. 131I SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm. 2003;18:61-69.
22. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
23. Johnson TK, McClure D, McCourt S. MABDOSE. I: characterization of a general purpose dose estimation code. Med Phys. 1999;26:1389-1395.
24. Johnson TK, McClure D, McCourt S. MABDOSE. II: validation of a general purpose dose estimation code. Med Phys. 1999;26:1396-1403.
25. Sgouros G, Barest G, Thekkumthala J, et al. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med. 1990;31:1884-1891.
26. Giap HB, Macey DJ, Bayouth JE, Boyer AL. Validation of a dose-point kernel convolution technique for internal dosimetry. Phys Med Biol. 1995;40:365-381.
27. Giap HB, Macey DJ, Podoloff DA. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. J Nucl Med. 1995;36:1885-1894.
28. Furhang EE, Sgouros G, Chui CS. Radionuclide photon dose kernels for internal emitter dosimetry. Med Phys. 1996;23:759-764.
29. Flux GD, Webb S, Ott RJ, Chittenden SJ, Thomas R. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging. J Nucl Med. 1997;38:1059-1066.
30. Kolbert KS, Sgouros G, Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997;38:301-308.
31. Erdi AK, Yorke ED, Loew MH, et al. Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy. Med Phys. 1998;25:2226-2233.
32. Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys. 1996;23:1523-1529.
33. Tagesson M, Ljungberg M, Strand SE. A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol. 1996;35:367-372.
34. Furhang EE, Chui CS, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys. 1997;24:1163-1172.
35. Liu A, Williams LE, Wong JY, Raubitschek AA. Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry. Nucl Med Biol. 1998;25:423-433.
36. Clairand I, Ricard M, Gouriou J, Di Paola M, Aubert B. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med. 1999;40:1517-1523.
37. Yoriyaz H, dos Santos A, Stabin MG, Cabezas R. Absorbed fractions in a voxel-based phantom calculated with the MCNP-4B code. Med Phys. 2000;27:1555-1562.
38. Yoriyaz H, Stabin MG, dos SA. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med. 2001;42:662-669.
39. Descalle MA, Hartmann Siantar CL, Dauffy L, et al. Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy. Cancer Biother Radiopharm. 2003;18:71-79.
40. Sgouros G, Kolbert KS. The three-dimensional internal dosimetry software package, 3D-ID. In: Zaidi H, Sgouros G, eds. Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine. Philadelphia, PA: Institute of Physics; 2002.
41. Sgouros G, Chiu S, Pentlow KS, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med. 1993;34:1595-1601.
42. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
43. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366-1372.
44. Kolbert KS, Sgouros G, Scott AM, et al. Dose-volume histogram representation of patient dose distribution in 3-dimensional internal dosimetry [abstract]. J Nucl Med. 1994;35:P123-P124.
45. Koral KF, Francis IR, Kroll S, et al. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method. Cancer. 2002;94:1258-1263.
46. 131I using Monte Carlo simulation. J Nucl Med. 2002;43:1101-1109.
47. Ljungberg M, Frey E, Sjogreen K, et al. 3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm. 2003;18:99-107.
48. Siegel JA, Wessels B, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm. 1990;3:213-233.
49. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
50. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102-2106.
51. Sgouros G, Stabin M, Erdi Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys. 2000;27:2150-2164.
52. Stabin MG, Siegel JA, Sparks RB. Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters. Cancer Biother Radiopharm. 2002;17:535-543.
53. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm. 2002;17:445-464.
54. Hindorf C, Linden O, Tennvall J, Wingardh K, Strand SE. Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer. 2002;94:1235-1239.
55. Shen S, Meredith RF, Duan J, et al. Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy. Cancer Biother Radiopharm. 2003;18:209-215.
56. 90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000-2018.
57. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
58. Meredith R, Shen S, Macey D, et al. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm. 2003;18:393-404.
59. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S-61S.
60. 90Y-labeled somatostatin analogues. J Nucl Med. 2005;46(suppl):92S-98S.
61. Wessels BW, Bolch WE, Bouchet LG, et al. Bone marrow dosimetry for radionuclide therapy: A multi-institutional comparison. J Nucl Med. 2004;45:1725-1733.
62. Zanzonico P, Sgouros G. Predicting myelotoxicity in radioimmunotherapy: what does dosimetry contribute? J Nucl Med. 1997;38:1753-1754.
63. Goddu SM, Howell RW, Giuliani DC, Rao DV. Biological dosimetry of bone marrow for incorporated yttrium-90. J Nucl Med. 1998;39:547-552.
64. Breitz HB, Fisher DR, Wessels BW. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med. 1998;39:1746-1751.
65. Wong JY, Wang J, Liu A, et al. Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy. Int J Radiat Oncol Biol Phys. 2000;46:599-607.
66. 90Y. J Nucl Med. 2001;42:162-169.
67. O'Donoghue JA, Baidoo N, Deland D, et al. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17:435-443.
68. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(suppl):14S-20S.
69. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I-131 tositumomab. Semin Oncol. 2003;30:31-38.
70. Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 2002;94:1349-1357.
71. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
72. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76.
73. Jokisch DW, Patton PW, Inglis BA, et al. NMR microscopy of trabecular bone and its role in skeletal dosimetry. Health Phys. 1998;75:584-596.
74. Bouchet LG, Jokisch DW, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone. J Nucl Med. 1999;40:1947-1966.
75. Rajon DA, Jokisch DW, Patton PW, Shah AP, Bolch WE. Voxel size effects in three-dimensional nuclear magnetic resonance microscopy performed for trabecular bone dosimetry. Med Phys. 2000;27:2624-2635.
76. Jokisch DW, Patton PW, Rajon DA, Inglis BA, Bolch WE. Chord distributions across 3D digital images of a human thoracic vertebra. Med Phys. 2001;28:1493-1504.
77. Bolch WE, Patton PW, Rajon DA, et al. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. J Nucl Med. 2002;43:97-108.
78. Rajon DA, Jokisch DW, Patton PW, et al. Voxel effects within digital images of trabecular bone and their consequences on chord-length distribution measurements. Phys Med Biol. 2002;47:1741-1759.
79. Rajon DA, Patton PW, Shah AP, Watchman CJ, Bolch WE. Surface area overestimation within three-dimensional digital images and its consequence for skeletal dosimetry. Med Phys. 2002;29:682-693.
80. Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm. 2002;17:427-433.
81. Shah AP, Patton PW, Rajon DA, Bolch WE. Adipocyte spatial distributions in bone marrow: implications for skeletal dosimetry models. J Nucl Med. 2003;44:774-783.
82. Rajon DA, Bolch WE. Marching cube algorithm: review and trilinear interpolation adaptation for image-based dosimetric models. Comput Med Imaging Graph. 2003;27:411-435.
83. Rajon DA, Shah AP, Watchman CJ, Brindle JM, Bolch WE. A hyperboliod representation of the bone-marrow interface within 3D NMR images of trabecular bone: applications to skeletal dosimetry. Phys Med Biol. 2003;48:1721-1740.
84. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-851.
85. 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552-1554.
86. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133-140.
87. Otte A, Weiner SM, Cybulla M. Is radiation nephropathy caused by yttrium-90? Lancet. 2002;359:979.
88. Giralt S, Bensinger W, Goodman M, et al. Ho-166-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood. 2003;102:2684-2691.
89. Lambert B, Cybulla M, Weiner SM, et al. Renal toxicity after radionuclide therapy. Radiat Res. 2004;161:607-611.
90. Russeva MG, Adams GP. Radioimmunotherapy with engineered antibodies. Expert Opinion Biol Ther. 2004;4:217-231.
91. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
92. Behr TM, Behe M, Angerstein C, et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res. 1999;5:3124s-3138s.
93. Breitz H, Wendt R, Stabin M, Bouchet L, Wessels B. Dosimetry of High Dose Skeletal Targeted Radiotherapy (STR) with (166)Ho-DOTMP. Cancer Biother Radiopharm. 2003;18:225-230.
94. Wessels B. Summary and perspectives on kidney dose-response to radionuclide therapy. Cancer Biother Radiopharm. 2004;19:388-390.
95. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363-370.
96. Sgouros G. Introduction to kidney dose-response for radionuclide therapy. Cancer Biother Radiopharm. 2004;19:357-358.
97. Breitz H. Clinical aspects of radiation nephropathy. Cancer Biother Radiopharm. 2004;19:359-362.
98. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm. 2004;19:378-387.
99. Green A, Flynn A, Pedley RB, Dearling J, Begent R. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture. Cancer Biother Radiopharm. 2004;19:371-377.
100. Howell RW, Rao DV, Sastry KS. Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med Phys. 1989;16:66-74.
101. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy [comments]. J Nucl Med. 1990;31:75-83.
102. Roberson PL, Heidorn DB, Kessler ML, Ten Haken RK, Buchsbaum DJ. Three-dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose-rate nonuniformity. Cancer. 1994;73:912-918.
103. Muthuswamy MS, Roberson PL, Ten Haken RK, Buchsbaum DJ. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography. Int J Radiat Oncol Biol Phys. 1996;35:165-172.
104. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341.
105. O'Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med. 2000;41:538-547.
106. Flynn AA, Pedley RB, Green AJ, et al. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images. Cancer Biother Radiopharm. 2001;16:391-400.
107. Flynn AA, Pedley RB, Green AJ, et al. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. Int J Radiat Biol. 2002;78:407-415.
108. Flynn AA, Pedley RB, Green AJ, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res. 2003;159:182-189.
109. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981-1997.
110. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-694.
111. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 1996;41:1871-1884.
112. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551-560.